4.7 Review

Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 141, Issue -, Pages 92-103

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2018.12.005

Keywords

CD40-CD40L pathway; Humoral immunity; Germinal center; Cell-mediated immunity; Autoimmunity; Novel therapeutics

Ask authors/readers for more resources

CD40 is a TNF receptor superfamily member expressed on both immune and non-immune cells. Interactions between B cell-expressed CD40 and its binding partner, CD40L, predominantly expressed on activated CD4+ T cells, play a critical role in promoting germinal center formation and the production of class-switched antibodies. Non-hematopoietic cells expressing CD40 can also engage CD40L and trigger a pro-inflammatory response. This article will highlight what is known about the biology of the CD40-CD40L axis in humans and describe the potential contribution of CD40 signaling on both hematopoietic and non-hematopoietic cells to autoimmune disease pathogenesis. Additionally, novel therapeutic approaches to target this pathway, currently being evaluated in clinical trials, are discussed. (C) 2018 The Authors. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available